FRX Fennec Pharmaceuticals Inc.

13.48USD19.29 CAD · TSX+0.63%Mkt Cap: 476.07M USDP/E: 482.25

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cispl…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap476.07M USD
Enterprise Value442.04M USD
Revenue (TTM)66.37M USD
Gross Profit40.88M USD
Net Income (TTM)-9.74M USD
Revenue/Share1.96 USD
Last Price13.48 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees35
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA31447P1009
Valuation
P/E (Trailing)482.25
P/E (Forward)12.88
PEG—
EV/EBITDA165.51
EV/Revenue6.66
P/S10.26
P/B9.83
EPS (TTM)0.04 USD
EPS (Forward)1.50 USD
52W Range
5.30696% of range13.87
52W High13.87 USD
52W Low5.306 USD
Profitability
Gross Margin91.57%
Oper. Margin5.60%
EBITDA Margin5.76%
Profit Margin-21.82%
ROE-27.46%
ROA-13.81%
ROIC—
ROCE-10.57%
Growth
Revenue Growth57.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.47M USD
CapEx (TTM)—
FCF Margin6.11%
FCF Yield0.85%
Net Debt-48.68M USD
Net Debt/EBITDA-12.74
Net Debt/FCF-12.01
Balance Sheet
Debt/Equity0.00
Current Ratio6.11
Quick Ratio5.47
Book Value/Sh1.96 USD
Cash/Share1.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:3
Split DateSep 5, 2014
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.35.31M
Float21.97M
Insiders13.93%
Institutions54.98%
Short Interest
Short Ratio78.1d
Short % Float0.08%
Short % Out.0.07%
Shares Short25.45K
Short (prev mo.)26.22K
Technical
SMA 5010.56 (+27.7%)
SMA 2009.163 (+47.2%)
Beta1.21
S&P 52W Chg12.00%
Avg Vol (30d)551
Avg Vol (10d)800
Technical Indicators
RSI (14)77.0
MACD0.9124
MACD Signal0.2829
MACD Hist.+0.6295
BB Upper13.53 USD
BB Middle10.78 USD
BB Lower8.040 USD
BB Width50.88%
ATR (14)0.4893 USD
Vol Ratio (20d)1.85x

About Fennec Pharmaceuticals (TSE: FRX)

›

Fennec Pharmaceuticals (TSE: FRX) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 35 employees.

The shares were at 19.29 CAD on 19 November 2026, up 52.2% over 52 weeks. Its 52-week range is 7.590 CAD to 19.84 CAD: the price is 2.8% below the high and 154.2% above the low.

At a market capitalisation of 681.04M CAD, it trades at 482.3 times trailing earnings and 12.9 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 1339% for FRX.

Fennec Pharmaceuticals reports return on equity of -27.5%, an operating margin of 5.6% and revenue up 57.3% year over year.

It holds more cash than debt, a net cash position of 48.68M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 23 March 2027.